Logo

Innovent Signs a Clinical Trial Agreement with Sirnaomics to Treat Cancer and Fibrotic Diseases in the US

Share this
Innovent Signs a Clinical Trial Agreement with Sirnaomics to Treat Cancer and Fibrotic Diseases in the US

Innovent Signs a Clinical Trial Agreement with Sirnaomics to Treat Cancer and Fibrotic Diseases in the US

Shots:
• The companies enter into a collaboration to conduct a study assessing the combination of Innovent's Tyvyt (sintilimab injection) and Sirnaomics' RNAi drug candidate STP705 (cotsiranib) in advanced cancers including Hepatocellular Carcinomas (HCC)
• The agreement will be the first example evaluating the combination of RNAi drug candidate- cotsiranib & immune checkpoint Ab- sintilimab to treat liver cancers
• Tyvyt is an immunoglobulin G4 mAb involved in binding PD-1 molecules and further blocks the interaction of the PD-1/ PD-L1 pathway and is jointly developed by Innovent and Lilly. STP705 is a siRNA therapeutic with the ability of dual-targeted inhibitory property and polypeptide nanoparticle (PNP)-enhanced delivery to knock down both TGF-β1 and COX-2 gene expression

Click here to read full press release/ article

Ref: PRNewswire | Image: Innovent

 


Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions